ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

AZN Astrazeneca Plc

10,830.00
-84.00 (-0.77%)
Last Updated: 11:35:31
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -84.00 -0.77% 10,830.00 10,826.00 10,830.00 10,934.00 10,764.00 10,914.00 306,125 11:35:31
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 45.81B 5.96B 3.8415 28.15 167.61B

ADRs End Higher; AstraZeneca Rises

16/11/2015 10:52pm

Dow Jones News


Astrazeneca (LSE:AZN)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Astrazeneca Charts.

International stocks trading in New York closed higher on Monday.

AstraZeneca PLC (AZN ,AZN.LN) was among the companies with ADRs that traded actively.

The BNY Mellon index of American depositary receipts rose 1.3% to 130.48. The European index increased 1.2% to 129.88, the Asian index improved 1.3% to 139.94, the Latin American index rose 1.6% to 163.61 and the emerging markets index increased 1.8% to 222.52.

 

AstraZeneca's ADRs rose 4.8% to $32.78 on Monday following Friday's announcement that the drug maker's lung-cancer treatment Tagrisso won U.S. regulatory approval after an unusually quick development process that took just 2 1/2 years. Tagrisso, previously known as AZD9291, is the first drug for a subset of lung-cancer patients whose tumors have spread and developed a treatment-resistant mutation called T790M. Another treatment for this group of patients, rociletinib from Clovis Oncology Inc., is being reviewed by U.S. regulators. Clovis said Monday that the Food and Drug Administration asked for additional data on rociletinib, a request that could delay potential approval of the treatment.

 

Banco Bradesco SA (BBDO, BBD, BBDC4.BR) plans to increase its capital by 3 billion reais ($782 million) by issuing 164.8 million new shares. The new shares will be divided almost evenly between ordinary and preferred shares. The Brazilian lender's shareholders will vote on the plan Dec. 17, the bank said Monday in a regulatory filing. ADRs rose 3% to $6.29.

 

JD.com (JD) reported that its third-quarter revenue grew 52% to $6.9 billion though the Chinese e-commerce company said its quarterly net loss widened sharply from the year-earlier period, with much of the loss stemming from higher expenses related to JD.com's expansion of its direct sales business and increased spending on marketing. The company expects sales for the current quarter to increase between 47% and 51%. ADRs rose 7.7% to $28.81.

 

Royal Dutch Shell PLC (RDSA, RDSA.LN) said that it is replacing the president of its Canadian subsidiary less than a month after abandoning a major oil sands project in the country. The moves come at a turbulent time for the energy industry as a prolonged slump in prices has squeezed profits, especially for high-cost operations such as oil sands and shale oil. ADRs fell 2.6% to $49.59.

 

Write to Tess Stynes at tess.stynes@wsj.com

 

Subscribe to WSJ: http://online.wsj.com?mod=djnwires


(END) Dow Jones Newswires

November 16, 2015 17:37 ET (22:37 GMT)

Copyright (c) 2015 Dow Jones & Company, Inc.

1 Year Astrazeneca Chart

1 Year Astrazeneca Chart

1 Month Astrazeneca Chart

1 Month Astrazeneca Chart

Your Recent History

Delayed Upgrade Clock